Trial Profile
An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Arterolane/piperaquine (Primary) ; Dihydroartemisinin/piperaquine
- Indications Falciparum malaria
- Focus Therapeutic Use
- 02 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 08 Jun 2015 New trial record